Kevin Oconnor insider trades: Albany Molecular Research (AMRI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kevin reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 31, 2016 | AMRI | ↓ Sell | 5,000 | $14.41 | $72K | Direct | Jun 1, 2016 (1d) |
| Mar 12, 2015 | AMRI | ↓ Sell | 5,000 | $18.22 | $91K | Direct | Mar 13, 2015 (1d) |
| Nov 20, 2007 | AMRI | ↑ Buy | 2,218 | $12.70 | $28K | Direct | Nov 21, 2007 (1d) |
| May 18, 2005 | AMRI | ↑ Buy | 1,687 | $11.85 | $20K | Direct | May 20, 2005 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kevin Oconnor's insider trades
Kevin Oconnor is a director at Albany Molecular Research (AMRI). Since May 18, 2005, Kevin has reported 2 open-market purchases worth $48K and 2 sales worth $163K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (20 filings), option exercises (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMRI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.